2433775-55-2
2433775-55-2
Chemical Structure
Selpercatinib-d3
Synonym(s): LOXO-292-d3
- CAS No.: 2433775-55-2
- Formula:C29H28D3N7O3
- Molecular Weight:528.62
InChIKey: XIIOFHFUYBLOLW-HPRDVNIFSA-N
SMILES: N#CC1=C2C(C3=CN=C(N4CC5N(C(C5)C4)CC6=CN=C(OC([2H])([2H])[2H])C=C6)C=C3)=CC(OCC(C)(O)C)=CN2N=C1
Biological Activity: Selpercatinib-d3 (LOXO-292-d3) is deuterium labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Selpercatinib-d3 | Selpercatinib-d3 (LOXO-292-d3) is deuterium labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selpercatinib (Standard) | ≥98% | Selpercatinib (Standard) is the analytical standard of Selpercatinib. This product is intended for research and analytical applications. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selpercatinib-13C,d3 | Selpercatinib-13C,d3 (LOXO-292-13C,d3) is 13C labeled Selpercatinib. Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Selpercatinib | 99.83% | Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Şentürk R, et, al. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122131. [Content Brief]
